AstraZeneca plc (NYSE:AZN) – Equities research analysts at Jefferies Group cut their FY2018 earnings per share estimates for AstraZeneca in a research note issued on Tuesday. Jefferies Group analyst J. Holford now anticipates that the company will post earnings per share of $1.78 for the year, down from their previous forecast of $1.94. Jefferies Group also issued estimates for AstraZeneca’s FY2019 earnings at $1.88 EPS, FY2020 earnings at $2.19 EPS, FY2021 earnings at $2.68 EPS and FY2022 earnings at $3.21 EPS.
AstraZeneca (NYSE:AZN) last released its quarterly earnings results on Thursday, November 9th. The company reported $1.12 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.57 by $0.55. The firm had revenue of $6.23 billion for the quarter, compared to analysts’ expectations of $6 billion. AstraZeneca had a net margin of 15.90% and a return on equity of 34.02%. The business’s revenue was up 9.4% on a year-over-year basis. During the same period in the prior year, the firm earned $1.32 EPS.
Other research analysts have also recently issued reports about the stock. Leerink Swann reissued a “market perform” rating and issued a $36.00 price target (up from $33.00) on shares of AstraZeneca in a report on Thursday. BNP Paribas raised shares of AstraZeneca from a “neutral” rating to an “outperform” rating in a report on Monday, September 25th. BMO Capital Markets reissued a “buy” rating and issued a $38.00 price target on shares of AstraZeneca in a report on Tuesday, November 7th. Citigroup raised shares of AstraZeneca to a “buy” rating in a report on Wednesday, October 18th. Finally, Zacks Investment Research raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, January 10th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and thirteen have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $34.48.
AstraZeneca (NYSE AZN) traded up $0.37 during trading on Wednesday, reaching $35.44. 2,527,393 shares of the company’s stock traded hands, compared to its average volume of 3,250,638. The company has a market cap of $88,630.00, a PE ratio of 25.31, a P/E/G ratio of 2.59 and a beta of 0.76. The company has a debt-to-equity ratio of 1.09, a quick ratio of 0.72 and a current ratio of 0.94. AstraZeneca has a 52-week low of $26.51 and a 52-week high of $35.92.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Wells Fargo & Company MN boosted its position in shares of AstraZeneca by 7.6% during the 3rd quarter. Wells Fargo & Company MN now owns 4,406,824 shares of the company’s stock worth $149,303,000 after acquiring an additional 310,389 shares in the last quarter. Point72 Asset Management L.P. boosted its position in shares of AstraZeneca by 103.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 1,224,939 shares of the company’s stock worth $41,501,000 after acquiring an additional 621,831 shares in the last quarter. Zions Bancorporation boosted its position in shares of AstraZeneca by 2,719.4% during the 3rd quarter. Zions Bancorporation now owns 38,852 shares of the company’s stock worth $1,317,000 after acquiring an additional 37,474 shares in the last quarter. Wrapmanager Inc. boosted its position in shares of AstraZeneca by 21.1% during the 3rd quarter. Wrapmanager Inc. now owns 52,340 shares of the company’s stock worth $1,773,000 after acquiring an additional 9,120 shares in the last quarter. Finally, BB&T Investment Services Inc. boosted its position in shares of AstraZeneca by 54.9% during the 3rd quarter. BB&T Investment Services Inc. now owns 23,136 shares of the company’s stock worth $782,000 after acquiring an additional 8,199 shares in the last quarter. 14.75% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This article was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another website, it was illegally stolen and reposted in violation of United States and international copyright and trademark law. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/01/19/astrazeneca-plc-forecasted-to-post-fy2018-earnings-of-1-78-per-share-azn.html.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.